Phio Pharmaceuticals Utdelning 2024

Vad gör Phio Pharmaceuticals?

Phio Pharmaceuticals Corp is a biopharmaceutical company focused on developing therapeutic products for the treatment of cancer and infectious diseases. The company is headquartered in Marlborough, Massachusetts and was founded in 1995. Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation) originated in Worcester, Massachusetts, when founders Craig Mello and other researchers at the University of Massachusetts Medical School discovered how RNA interference (RNAi) could be used to combat diseases. The RNAi technology aims to manipulate the DNA code in cells to block the production of proteins related to disease. This technology has the potential to revolutionize the therapeutic landscape by enabling faster, more efficient, and more precise treatments than previous approaches. Phio has developed unique technologies to selectively deliver RNAi molecules to cancer tissue. The technology utilizes a family of compounds called "self-delivering RNA" (sd-rxRNA). These molecules are capable of targeting cancer cells and destroying them from within without affecting healthy cells. Phio believes that its technology has the potential for broad applications in cancer therapy and aims to treat a variety of cancer types. Phio has also developed a technology platform called "immunostimulatory RNA" (isRNA) that aims to activate the body's immune system to recognize and attack cancer cells. When injected into cancer cells, isRNA molecules can cause the immune system to recognize and attack the cancer cells as foreign. This technology has the potential to create a new class of immunotherapeutics that combines the benefits of RNAi and immunotherapy. Phio also has products in the development phase for the treatment of infectious diseases. It has developed an siRNA program for the inhibition of hepatitis B and is currently working on the development of therapeutics against dengue fever and the Zika virus. Phio has a partnership with the Karolinska Institutet, a world-leading medical university in Stockholm, Sweden, to further develop its sd-rxRNA technology. The collaboration aims to confirm the efficacy and safety of the technology and explore potential new applications in cancer therapy and other disease areas. Phio considers its sd-rxRNA products as a potentially disruptive technology that can reduce the need for conventional chemotherapy and radiation therapies, which can have high toxicity and severe side effects in many patients. The technology has the potential to create effective therapies with minimal side effects. Overall, Phio is an emerging company with a promising technology platform that has the potential to fundamentally change the therapeutic landscape. The partnership with a leading medical university and the comprehensive development pipeline suggest that the company is on track to conduct clinical trials in the near future and possibly achieve successful market launches. Phio Pharmaceuticals är ett av de mest populära företagen på Eulerpool.com.